SGLT2 Inhibitors and TZD for Type 2 Diabetes on DPP4 Inhibitors

This clinical trial is designed to explore new ways to improve blood sugar control in people with type 2 diabetes who are already taking a type of medication known as DPP4 inhibitors. The study tests three different strategies: using an SGLT2 inhibitor alone, using a TZD alone, or combining both medications, compared to continuing with just the DPP4 inhibitor. The goal is to see if adding these medications can better manage blood sugar levels, which is crucial for preventing complications of diabetes. This trial is important for adults between 19 and 75 years old with type 2 diabetes who have been on stable diabetes medication. Participants in the study will be randomly placed into one of four groups. Each group will follow a specific medication plan for either 12 or 24 weeks. The main focus is on changes in HbA1c levels, a marker of long-term blood sugar control. Researchers will also look at other factors like fasting and after-meal blood sugar levels, insulin levels, cholesterol, and body composition. The trial is conducted at multiple hospitals in Korea, with all medications provided by the study sponsor. Participants will also receive advice on diet and exercise to support their treatment. Regular safety checks will ensure any side effects are promptly addressed.